14.06.2011 • NewsSamsung LEDOsramSiemens

Samsung LED Launches Patent Countersuit Against Osram

Samsung LED said on Sunday it had filed a patent infringement lawsuit against Osram Korea Co. and two other Korean sales agents of German lightbulb maker Osram at a Seoul district court.       

Samsung LED said in a statement the lawsuit was in response to a patent suit brought against it by Osram.       

The eight patents-in-suit relate to light emitting diodes (LED) chip and package technology used in LED light lenses and high power applications, the joint venture led by Samsung Electronics and Sumitomo Chemical said.

Siemens said on June 6 its lightbulb unit Osram was suing its two Korean rivals, Samsung and LG groups of companies, in four countries including the United States, for alleged infringement of patents on LED technology.       

Osram is the world's No.2 lighting company after Philips and ahead of General Electric.       

"The Korean suit is Samsung LED's first response to Osram's initiation of lawsuits against Samsung LED in the U.S. and Germany," Samsung said.       

Samsung LED claims it currently has about 700 U.S. patents and patent applications and about 2,000 Korean patents and patent applications.       

LEDs are electronic semiconductor devices that emit light and are more energy efficient.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.